Department of Clinical Laboratory Sciences, College of Applied Medical Sciences-AlQurayyat, Jouf University, Saudi Arabia.
Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Victoria, Australia.
Blood Coagul Fibrinolysis. 2022 Apr 1;33(3):149-152. doi: 10.1097/MBC.0000000000001116. Epub 2022 Mar 2.
Deep vein thrombosis (DVT) is a critical condition and a potential cause of mortality and morbidity in Africa and worldwide with a high recurrence rate. The study was designed to assess the roles of natural anticoagulants and fibrinolytic regulatory factors in the development of DVT in Sudanese patients. A case-control study was conducted in Omdurman Teaching Hospital, Khartoum State over a period of 1 year. The study enrolled 200 patients diagnosed with DVT and 200 age-matched and gender-matched controls. Demographic data and data on acquired risk factors were collected using a semi-structured questionnaire. Protein C (PC), protein S (PS), antithrombin III (AT-III), thrombin-activable fibrinolysis inhibitor (TAFI), and plasminogen activator inhibitor-1 (PAI-1) were measured in patients and controls. Among the patients with DVT, 5.5% had PC deficiency, 8.5% had PS deficiency, and 3% had AT-III deficiency. Elevated TAFI and PAI-1 levels were demonstrated in 1.5 and 0.5% of patients, respectively. Risk factors for DVT (overweight, surgical history, and family history of DVT) were remarkably higher in patients than in controls. Among the female participants, pregnancy and usage of oral contraceptive pills were the highest associated risk factors for DVT. The findings concluded that the early assessment of risk factors, including the measurements of natural inhibitors, can predict the occurrence of DVT before it is actually detected in patients.
深静脉血栓形成（DVT）是一种严重的疾病，在非洲和全球范围内是导致死亡率和发病率的潜在原因，且复发率较高。本研究旨在评估天然抗凝剂和纤维蛋白溶解调节因子在苏丹患者 DVT 发展中的作用。在喀土穆州奥姆杜尔曼教学医院进行了为期 1 年的病例对照研究。该研究纳入了 200 例诊断为 DVT 的患者和 200 名年龄和性别匹配的对照者。使用半结构式问卷收集人口统计学数据和获得性危险因素数据。在患者和对照者中测量了蛋白 C（PC）、蛋白 S（PS）、抗凝血酶 III（AT-III）、凝血酶激活的纤维蛋白溶解抑制剂（TAFI）和纤溶酶原激活物抑制剂-1（PAI-1）。在 DVT 患者中，5.5%存在 PC 缺乏，8.5%存在 PS 缺乏，3%存在 AT-III 缺乏。分别有 1.5%和 0.5%的患者存在 TAFI 和 PAI-1 水平升高。与对照组相比，DVT 的风险因素（超重、手术史和 DVT 家族史）在患者中显著更高。在女性参与者中，妊娠和口服避孕药的使用是 DVT 的最高相关危险因素。研究结果表明，早期评估风险因素，包括天然抑制剂的测量，可以在患者实际检测到 DVT 之前预测其发生。
